Our biotech team launched this gene therapy startup two years ago and we've developed completely different risk tolerances around patient safety data. Half of us want to push for accelerated approval based on our Phase II results and half think we need another full trial, and every safety meeting turns into the same philosophical argument about acceptable risk that we never actually resolve.
More people experience this than they realize.
A founding team is paralyzed by fundamentally different beliefs about acceptable risk when human lives are in the balance.
“Where Are You with Science — Biotech & Pharmaceutical R&D?”
Peri can explain why this happens, help you decide if this is the right situation for you, and point toward the right journey or coach.
If this sounds familiar, the Library can help you find the bigger picture.